IHS Chemical Week

Chemical Week Magazine :: New Construction Projects

Merck KGaA Builds Plant in Switzerland

1:38 PM MDT | January 24, 2007 | Chemical Week Editorial Staff

Merck KGaA says it will build a plant near Geneva to manufacture the company’s Erbitux monoclonal antibody cancer treatment. The announcement was made shortly after Merck KGaA completed the acquisition of a majority stake in biotechnology firm Serono (Geneva) and created a new division, Merck Serono (CW, Jan. 17, p. 23). Merck KGaA had previously planned to build the Erbitux plant at its Darmstadt, Germany...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa